Jaguar Health Flags Going Concern Doubt Despite $19M License Windfall
JAGX sits 33% above its 52-week low of $0.725.
Summary
Jaguar Health's Q2 2026 10-Q discloses a going concern warning, $3.8M cash, and a $4.1M net loss, despite a $19M licensing deal that improved equity to $4.9M.
Key Events · Earnings and Guidance · JAGX
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern over the next 12 months, citing recurring losses and insufficient cash balances.
-
Cash Position
Cash of $3.8 million and restricted cash of $2.8 million as of June 30, 2026, down from $7.8 million total at the start of the year.
-
Net Loss
Net loss of $4.1 million for the six months ended June 30, 2026, improved from a $21.2 million loss in the prior-year period.
-
License Revenue
Recognized $19.0 million in license revenue from the Woodward agreement, including a $16.0 million upfront fee and a $3.0 million fee to extinguish a repurchase option.
Analysis · JAGX · Life Sciences
Jaguar Health's Q2 2026 10-Q reveals a going concern warning, with cash of just $3.8 million and restricted cash of $2.8 million. The company posted a net loss of $4.1 million for the first half of 2026, though a $19.0 million licensing deal with Woodward provided a lifeline. Total liabilities fell sharply to $29.3 million from $57.0 million, and stockholders' equity swung to a positive $4.9 million from a deficit of $18.7 million. However, the company remains under a Nasdaq Mandatory Panel Monitor until May 2027, and a new SEC-approved listing standard requiring a $5.0 million market value of listed securities is currently stayed. The going concern language is the key risk: management states existing cash may not fund operations for one year.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.9% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.73 to $85.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.